Viking Therapeutics Stock Forecast, Price & News

-0.27 (-4.22 %)
(As of 06/18/2021 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume145,908 shs
Average Volume1.22 million shs
Market Capitalization$478.75 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Viking Therapeutics logo

About Viking Therapeutics

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRÃ), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRÃ for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.90 out of 5 stars

Medical Sector

127th out of 2,100 stocks

Pharmaceutical Preparations Industry

55th out of 831 stocks

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions

Is Viking Therapeutics a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Viking Therapeutics stock.
View analyst ratings for Viking Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Viking Therapeutics?

Wall Street analysts have given Viking Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Viking Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Viking Therapeutics' next earnings date?

Viking Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Viking Therapeutics

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics, Inc. (NASDAQ:VKTX) issued its earnings results on Wednesday, April, 28th. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.01.
View Viking Therapeutics' earnings history

How has Viking Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Viking Therapeutics' stock was trading at $5.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VKTX stock has increased by 25.4% and is now trading at $6.36.
View which stocks have been most impacted by COVID-19

What price target have analysts set for VKTX?

9 brokers have issued 1-year price objectives for Viking Therapeutics' shares. Their forecasts range from $12.00 to $21.00. On average, they anticipate Viking Therapeutics' share price to reach $15.38 in the next year. This suggests a possible upside of 141.7% from the stock's current price.
View analysts' price targets for Viking Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Viking Therapeutics' key executives?

Viking Therapeutics' management team includes the following people:
  • Dr. Brian Lian Ph.D., Pres, CEO & Director (Age 55, Pay $878k)
  • Mr. Gregory S. Zante, Chief Financial Officer (Age 50)
  • Ms. Marianne Mancini, Chief Operating Officer (Age 56)
  • Mr. Michael Morneau, VP of Fin. & Admin. (Age 56)

Who are some of Viking Therapeutics' key competitors?

What other stocks do shareholders of Viking Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Advanced Micro Devices (AMD), Verastem (VSTM), Energy Transfer (ET) and Inovio Pharmaceuticals (INO).

When did Viking Therapeutics IPO?

(VKTX) raised $20 million in an IPO on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.

What is Viking Therapeutics' stock symbol?

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

Who are Viking Therapeutics' major shareholders?

Viking Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.82%), Park West Asset Management LLC (2.05%), Fiera Capital Corp (1.43%), Geode Capital Management LLC (1.36%), Northern Trust Corp (1.28%) and Ikarian Capital LLC (0.93%). Company insiders that own Viking Therapeutics stock include Ligand Pharmaceuticals Inc and Matthew W Foehr.
View institutional ownership trends for Viking Therapeutics

Which institutional investors are selling Viking Therapeutics stock?

VKTX stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Credit Suisse AG, Virginia Retirement Systems ET AL, Bank of Montreal Can, Brinker Capital Investments LLC, Goldman Sachs Group Inc., UBS Asset Management Americas Inc., and GSA Capital Partners LLP. Company insiders that have sold Viking Therapeutics company stock in the last year include Ligand Pharmaceuticals Inc, and Matthew W Foehr.
View insider buying and selling activity for Viking Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Viking Therapeutics stock?

VKTX stock was acquired by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Citigroup Inc., Rafferty Asset Management LLC, UBS Group AG, Dimensional Fund Advisors LP, Park West Asset Management LLC, Geode Capital Management LLC, and Squarepoint Ops LLC.
View insider buying and selling activity for Viking Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Viking Therapeutics?

Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Viking Therapeutics' stock price today?

One share of VKTX stock can currently be purchased for approximately $6.36.

How much money does Viking Therapeutics make?

Viking Therapeutics has a market capitalization of $496.72 million. The biotechnology company earns $-39,490,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.

How many employees does Viking Therapeutics have?

Viking Therapeutics employs 18 workers across the globe.

What is Viking Therapeutics' official website?

The official website for Viking Therapeutics is

Where are Viking Therapeutics' headquarters?

Viking Therapeutics is headquartered at 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130.

How can I contact Viking Therapeutics?

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.